Eli Lilly's Oral Weight Loss Drug Stumbles Out of the Gate: Prescriptions Just 1/5 of Novo Nord

Eli Lilly's newly launched oral weight loss drug Foundayo managed just 3,707 prescriptions in its second week on the market. In contrast, Novo Nordisk's oral version of Wegovy hit 18,410 over the same period.  The nearly 5x gap sent Eli Lilly shares down 8% pre-market, while Novo Nordisk rose 4%. On the surface, this is an early-stage prescription comparison. But what really matters is that the market is voting with its feet: Novo Nordisk may have already seized the starting advantage in the new oral weight loss drug race. ### Behind the Prescription Gap: More Than 'Early Noise' RBC analysts argue that early comparisons are limited—sample distribution and telemedicine prescriptions are hard to track, and real performance won't be clear for two to three months. That's fair, but the market isn't buying it. Why? Because oral weight loss drugs are seen as the next frontier in obesity treatment. Both giants are extending their battle from injectables to pills. Whoever gets it right first will lock in a key position in the next competitive cycle. Novo Nordisk's oral Wegovy launched in January and has already become a key pillar of its business recovery. Eli Lilly's Foundayo, approved via the FDA's accelerated pathway, was expected to be a strong contender. But the first-week data showed a stark gap. The market knows early data is noisy, but at this point, any 'below expectations' signal gets amplified. Eli Lilly leads in injectables, but oral is a must-win battlefield. ### Oral Drug Race: Does Novo Have a Better Product? No head-to-head trials have been conducted yet, but Phase 3 data from each drug hints at the difference. Eli Lilly's own large study showed Foundayo's weight loss was less than what Novo Nordisk reported in a separate trial for oral Wegovy. While trial designs differ and direct comparisons aren't valid, investors have their own scales. Novo's oral Wegovy uses semaglutide, the same active ingredient as its injectable Wegovy and Ozempic, backed by a deep safety and efficacy track record. Eli Lilly's Foundayo is a new molecule, with the advantage of fewer restrictions—no fasting or waiting 30 minutes before eating or drinking. Convenience vs. efficacy: the market is currently betting on efficacy. ### Eli Lilly Leads in Injectables; Oral Is Novo's Comeback In the injectable market, Eli Lilly's Zepbound beat Novo Nordisk's Wegovy in a head-to-head trial, showing superior weight loss. Novo lost its early leadership in injectable obesity drugs. So oral drugs are huge for Novo. Winning this new front could offset its losses in injectables and re-establish its competitive edge. Right now, Novo looks well-positioned. Oral Wegovy launched earlier, prescriptions are growing faster, and the market has given it an initial nod. Eli Lilly faces the pressure of a slow start. ### What to Watch Next Real prescription data in two to three months is the first key milestone. If Foundayo's numbers ramp up quickly and close the gap, the current dip could be a buying opportunity. If the gap persists, Eli Lilly's oral story loses credibility. Also, head-to-head trial results are inevitable. That will be the true 'throne match.' Whoever proves their oral drug is superior in a direct comparison will dominate the space. For investors, it's too early to conclude, but it's time to track two metrics: prescription trends and head-to-head data. The obesity drug market has moved from 'concept hype' to 'product delivery.' The drugs that actually perform will capture the next wave of gains. The Eli Lilly vs. Novo Nordisk showdown is far from over, but the first round score is already on the board.